Publications

Publications pour l'équipe Oncostat

Titre Publication Type Publication year Auteur
Improved Treatment of Breast Cancer with Anti-HER2 Therapy Requires Interleukin-21 Signaling in CD8+ T Cells journalArticle 2016 Mittal, D.; Caramia, F.; Michiels, S.; Joensuu, H.; Kellokumpu-Lehtinen, P. L.; Sotiriou, C.; Loi, S.; Smyth, M. J.
Uncovering Professional Attitudes Toward Treatment of Rare Carcinomas of the Breast: An International Practice e-Survey Involving 32 Countries journalArticle 2016 Saghatchian, M.; Fadoukhair, Z.; Hofert, K.; Lanoy, E.; Mathieu, M. C.; Mazouni, C.; Delaloge, S.
Human metapneumovirus in patients hospitalized with acute respiratory infections: A meta-analysis journalArticle 2016 Lefebvre, A.; Manoha, C.; Bour, J. B.; Abbas, R.; Fournel, I.; Tiv, M.; Pothier, P.; Astruc, K.; Aho-Glele, L. S.
Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial journalArticle 2016 Piperno-Neumann, S.; Le Deley, M. C.; Redini, F.; Pacquement, H.; Marec-Berard, P.; Petit, P.; Brisse, H.; Lervat, C.; Gentet, J. C.; Entz-Werle, N.; Italiano, A.; Corradini, N.; Bompas, E.; Penel, N.; Tabone, M. D.; Gomez-Brouchet, A.; Guinebretiere, J. M.; Mascard, E.; Gouin, F.; Chevance, A.; Bonnet, N.; Blay, J. Y.; Brugieres, L.; Sarcoma Group of, Unicancer; French Society of Pediatric, Oncology; French Sarcoma, Group
Prognostic and Predictive Effect of TP53 Mutations in Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis journalArticle 2016 Ma, X.; Le Teuff, G.; Lacas, B.; Tsao, M. S.; Graziano, S.; Pignon, J. P.; Douillard, J. Y.; Le Chevalier, T.; Seymour, L.; Filipits, M.; Pirker, R.; Janne, P. A.; Shepherd, F. A.; Brambilla, E.; Soria, J. C.; Hainaut, P.; Group, L. A. C. E. Bio Collaborative
Impact of dermatologic adverse events induced by targeted therapies on quality of life journalArticle 2016 Charles, C.; Bungener, C.; Razavi, D.; Mateus, C.; Routier, E.; Lanoy, E.; Verschoore, M.; Robert, C.; Dauchy, S.
Intensity Modulated Proton Therapy Versus Intensity Modulated Photon Radiation Therapy for Oropharyngeal Cancer: First Comparative Results of Patient-Reported Outcomes journalArticle 2016 Sio, T. T.; Lin, H. K.; Shi, Q.; Gunn, G. B.; Cleeland, C. S.; Lee, J. J.; Hernandez, M.; Blanchard, P.; Thaker, N. G.; Phan, J.; Rosenthal, D. I.; Garden, A. S.; Morrison, W. H.; Fuller, C. D.; Mendoza, T. R.; Mohan, R.; Wang, X. S.; Frank, S. J.
Postoperative radiotherapy for non-small cell lung cancer journalArticle 2016 Burdett, S.; Rydzewska, L.; Tierney, J.; Fisher, D.; Parmar, M. K.; Arriagada, R.; Pignon, J. P.; Le Pechoux, C.; Group, Port Meta-analysis Trialists
Phenotypic and genetic heterogeneity of tumor tissue and circulating tumor cells in patients with metastatic castration-resistant prostate cancer: A report from the PETRUS prospective study journalArticle 2016 Massard, C.; Oulhen, M.; Le Moulec, S.; Auger, N.; Foulon, S.; Abou-Lovergne, A.; Billiot, F.; Valent, A.; Marty, V.; Loriot, Y.; Fizazi, K.; Vielh, P.; Farace, F.
Treatment of squamous cell carcinoma of the posterior pharyngeal wall: Radiotherapy versus surgery journalArticle 2016 De Felice, F.; Blanchard, P.; Levy, A.; Nguyen, F.; Gorphe, P.; Janot, F.; Temam, S.; Tao, Y.
Clinical Outcomes and Patterns of Disease Recurrence After Intensity Modulated Proton Therapy for Oropharyngeal Squamous Carcinoma journalArticle 2016 Gunn, G. B.; Blanchard, P.; Garden, A. S.; Zhu, X. R.; Fuller, C. D.; Mohamed, A. S.; Morrison, W. H.; Phan, J.; Beadle, B. M.; Skinner, H. D.; Sturgis, E. M.; Kies, M. S.; Hutcheson, K. A.; Rosenthal, D. I.; Mohan, R.; Gillin, M. T.; Frank, S. J.
Phase I trial evaluating the antiviral agent Cidofovir in combination with chemoradiation in cervical cancer patients journalArticle 2016 Deutsch, E.; Haie-Meder, C.; Bayar, M. A.; Mondini, M.; Laporte, M.; Mazeron, R.; Adam, J.; Varga, A.; Vassal, G.; Magne, N.; Chargari, C.; Lanoy, E.; Pautier, P.; Levy, A.; Soria, J. C.
Treatment of squamous cell carcinoma of the posterior pharyngeal wall: Radiotherapy versus surgery journalArticle 2016 De Felice, F.; Blanchard, P.; Levy, A.; Nguyen, F.; Gorphe, P.; Janot, F.; Temam, S.; Tao, Y.
Quelles exigences pour qu'un biomarqueur puisse être un critère de substitution acceptable ? journalArticle 2016 Paoletti, X.; Rotolo, F.; Michiels, S.
Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours journalArticle 2016 Gizzi, M.; Oberic, L.; Massard, C.; Poterie, A.; Gwenael, L. T.; Loriot, Y.; Albiges, L.; Baciarello, G.; Michels, J.; Bossi, A.; Blanchard, P.; Escudier, B.; Fizazi, K.
Percutaneous Thermal Ablation of Breast Cancer Metastases in Oligometastatic Patients journalArticle 2016 Barral, M.; Auperin, A.; Hakime, A.; Cartier, V.; Tacher, V.; Otmezguine, Y.; Tselikas, L.; de Baere, T.; Deschamps, F.
Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease journalArticle 2016 Marthey, L.; Mateus, C.; Mussini, C.; Nachury, M.; Nancey, S.; Grange, F.; Zallot, C.; Peyrin-Biroulet, L.; Rahier, J. F.; Bourdier de Beauregard, M.; Mortier, L.; Coutzac, C.; Soularue, E.; Lanoy, E.; Kapel, N.; Planchard, D.; Chaput, N.; Robert, C.; Carbonnel, F.
The ENCCA-WP7/EuroSarc/EEC/PROVABES/EURAMOS 3rd European Bone Sarcoma Networking Meeting/Joint Workshop of EU Bone Sarcoma Translational Research Networks; Vienna, Austria, September 24-25, 2015. Workshop Report journalArticle 2016 Kager, L.; Whelan, J.; Dirksen, U.; Hassan, B.; Anninga, J.; Bennister, L.; Bovee, Jvmg; Brennan, B.; Broto, J. M.; Brugieres, L.; Cleton-Jansen, A. M.; Copland, C.; Dutour, A.; Fagioli, F.; Ferrari, S.; Fiocco, M.; Fleuren, E.; Gaspar, N.; Gelderblom, H.; Gerrand, C.; Gerss, J.; Gonzato, O.; van der Graaf, W.; Hecker-Nolting, S.; Herrero-Martin, D.; Klco-Brosius, S.; Kovar, H.; Ladenstein, R.; Lancia, C.; LeDeley, M. C.; McCabe, M. G.; Metzler, M.; Myklebost, O.; Nathrath, M.; Picci, P.; Potratz, J.; Redini, F.; Richter, G. H. S.; Reinke, D.; Rutkowski, P.; Scotlandi, K.; Strauss, S.; Thomas, D.; Tirado, O. M.; Tirode, F.; Vassal, G.; Bielack, S. S.
Empirical extensions of the lasso penalty to reduce the false discovery rate in high-dimensional Cox regression models journalArticle 2016 Ternes, N.; Rotolo, F.; Michiels, S.
Impact of dermatologic adverse events induced by targeted therapies on quality of life journalArticle 2016 Charles, C.; Bungener, C.; Razavi, D.; Mateus, C.; Routier, E.; Lanoy, E.; Verschoore, M.; Robert, C.; Dauchy, S.
Statistical controversies in clinical research: prognostic gene signatures are not (yet) useful in clinical practice journalArticle 2016 Michiels, S.; Ternes, N.; Rotolo, F.
Phase I trial evaluating the antiviral agent Cidofovir in combination with chemoradiation in cervical cancer patients journalArticle 2016 Deutsch, E.; Haie-Meder, C.; Bayar, M. A.; Mondini, M.; Laporte, M.; Mazeron, R.; Adam, J.; Varga, A.; Vassal, G.; Magne, N.; Chargari, C.; Lanoy, E.; Pautier, P.; Levy, A.; Soria, J. C.
Outcome According to Elective Pelvic Radiation Therapy in Patients With High-Risk Localized Prostate Cancer: A Secondary Analysis of the GETUG 12 Phase 3 Randomized Trial journalArticle 2016 Blanchard, P.; Faivre, L.; Lesaunier, F.; Salem, N.; Mesgouez-Nebout, N.; Deniau-Alexandre, E.; Rolland, F.; Ferrero, J. M.; Houede, N.; Mourey, L.; Theodore, C.; Krakowski, I.; Berdah, J. F.; Baciuchka, M.; Laguerre, B.; Davin, J. L.; Habibian, M.; Culine, S.; Laplanche, A.; Fizazi, K.
Outcome According to Elective Pelvic Radiation Therapy in Patients With High-Risk Localized Prostate Cancer: A Secondary Analysis of the GETUG 12 Phase 3 Randomized Trial journalArticle 2016 Blanchard, P.; Faivre, L.; Lesaunier, F.; Salem, N.; Mesgouez-Nebout, N.; Deniau-Alexandre, E.; Rolland, F.; Ferrero, J. M.; Houede, N.; Mourey, L.; Theodore, C.; Krakowski, I.; Berdah, J. F.; Baciuchka, M.; Laguerre, B.; Davin, J. L.; Habibian, M.; Culine, S.; Laplanche, A.; Fizazi, K.
Prognostic and Predictive Effect of TP53 Mutations in Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis journalArticle 2016 Ma, X.; Le Teuff, G.; Lacas, B.; Tsao, M. S.; Graziano, S.; Pignon, J. P.; Douillard, J. Y.; Le Chevalier, T.; Seymour, L.; Filipits, M.; Pirker, R.; Janne, P. A.; Shepherd, F. A.; Brambilla, E.; Soria, J. C.; Hainaut, P.; Group, L. A. C. E. Bio Collaborative
Cardiac troponin I elevation and overall survival among cancer patients receiving investigational compounds during phase I trials journalArticle 2016 Hollebecque, A.; Lanoy, E.; Troallen, F.; Soulat-Dufour, L.; Massard, C.; Bahleda, R.; Varga, A.; Gazzah, A.; Postel-Vinay, S.; Ribrag, V.; Deutsch, E.; Angevin, E.; Boccara, F.; Cohen, A.; Soria, J. C.; Ederhy, S.
The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence journalArticle 2016 Ignatiadis, M.; Azim, H. A.; Desmedt, C.; Veys, I.; Larsimont, D.; Salgado, R.; Lyng, M. B.; Viale, G.; Leyland-Jones, B.; Giobbie-Hurder, A.; Kammler, R.; Dell'Orto, P.; Rothe, F.; Laios, I.; Ditzel, H. J.; Regan, M. M.; Piccart, M.; Michiels, S.; Sotiriou, C.
Joint model for left-censored longitudinal data, recurrent events and terminal event: Predictive abilities of tumor burden for cancer evolution with application to the FFCD 2000-05 trial journalArticle 2016 Krol, A.; Ferrer, L.; Pignon, J. P.; Proust-Lima, C.; Ducreux, M.; Bouche, O.; Michiels, S.; Rondeau, V.
Can postoperative radiotherapy be omitted in localised standard-risk Ewing sarcoma? An observational study of the Euro-E.W.I.N.G group journalArticle 2016 Foulon, S.; Brennan, B.; Gaspar, N.; Dirksen, U.; Jeys, L.; Cassoni, A.; Claude, L.; Seddon, B.; Marec-Berard, P.; Whelan, J.; Paulussen, M.; Streitbuerger, A.; Oberlin, O.; Juergens, H.; Grimer, R.; Le Deley, M. C.
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination journalArticle 2016 Boutros, C.; Tarhini, A.; Routier, E.; Lambotte, O.; Ladurie, F. L.; Carbonnel, F.; Izzeddine, H.; Marabelle, A.; Champiat, S.; Berdelou, A.; Lanoy, E.; Texier, M.; Libenciuc, C.; Eggermont, A. M.; Soria, J. C.; Mateus, C.; Robert, C.
The 5000% case: a glimpse into the financial issue of lung cancer treatment journalArticle 2016 Remon, J.; Bonastre, J.; Besse, B.
Toward a model-based patient selection strategy for proton therapy: External validation of photon-derived normal tissue complication probability models in a head and neck proton therapy cohort journalArticle 2016 Blanchard, P.; Wong, A. J.; Gunn, G. B.; Garden, A. S.; Mohamed, A. S.; Rosenthal, D. I.; Crutison, J.; Wu, R.; Zhang, X.; Zhu, X. R.; Mohan, R.; Amin, M. V.; Fuller, C. D.; Frank, S. J.
Mutation-Independent Activation of the Anaplastic Lymphoma Kinase in Neuroblastoma journalArticle 2016 Regairaz, M.; Munier, F.; Sartelet, H.; Castaing, M.; Marty, V.; Renauleaud, C.; Doux, C.; Delbe, J.; Courty, J.; Fabre, M.; Ohta, S.; Vielh, P.; Michiels, S.; Valteau-Couanet, D.; Vassal, G.
Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours journalArticle 2016 Gizzi, M.; Oberic, L.; Massard, C.; Poterie, A.; Gwenael, L. T.; Loriot, Y.; Albiges, L.; Baciarello, G.; Michels, J.; Bossi, A.; Blanchard, P.; Escudier, B.; Fizazi, K.
Results of a multicenter phase I dose-finding trial of hyperthermic intraperitoneal cisplatin after neoadjuvant chemotherapy and complete cytoreductive surgery and followed by maintenance bevacizumab in initially unresectable ovarian cancer journalArticle 2016 Gouy, S.; Ferron, G.; Glehen, O.; Bayar, A.; Marchal, F.; Pomel, C.; Quenet, F.; Bereder, J. M.; Le Deley, M. C.; Morice, P.
Equal access to innovative therapies and precision cancer care journalArticle 2016 Buzyn, A.; Blay, J. Y.; Hoog-Labouret, N.; Jimenez, M.; Nowak, F.; Deley, M. C.; Perol, D.; Cailliot, C.; Raynaud, J.; Vassal, G.
Modalités de surveillance des patients suivis pour un cancer de la prostate avancé : résultats d’une enquête nationale de pratique journalArticle 2016 Rozet, F.; Roupret, M.; Hennequin, C.; Massard, C.; Blanchard, P.; Le moulec, S.
Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents journalArticle 2016 Merlevede, J.; Droin, N.; Qin, T.; Meldi, K.; Yoshida, K.; Morabito, M.; Chautard, E.; Auboeuf, D.; Fenaux, P.; Braun, T.; Itzykson, R.; de Botton, S.; Quesnel, B.; Commes, T.; Jourdan, E.; Vainchenker, W.; Bernard, O.; Pata-Merci, N.; Solier, S.; Gayevskiy, V.; Dinger, M. E.; Cowley, M. J.; Selimoglu-Buet, D.; Meyer, V.; Artiguenave, F.; Deleuze, J. F.; Preudhomme, C.; Stratton, M. R.; Alexandrov, L. B.; Padron, E.; Ogawa, S.; Koscielny, S.; Figueroa, M.; Solary, E.
Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials journalArticle 2016 Le Tourneau, C.; Kamal, M.; Tsimberidou, A. M.; Bedard, P.; Pierron, G.; Callens, C.; Rouleau, E.; Vincent-Salomon, A.; Servant, N.; Alt, M.; Rouzier, R.; Paoletti, X.; Delattre, O.; Bieche, I.
Variation in rates of breast cancer surgery: A national analysis based on French Hospital Episode Statistics journalArticle 2016 Rococo, E.; Mazouni, C.; Or, Z.; Mobillion, V.; Koon Sun Pat, M.; Bonastre, J.